Company

Delphia Therapeutics

Biotechnology Research One Kendall Sq, Bldg. 200 29 employees

Employees: 29
Contacts: 3
Emails: 3
Phones: 2

www.delphiatx.com LinkedIn Crunchbase

Delphia Therapeutics Overview

Headquarters: One Kendall Sq, Bldg. 200
Website: www.delphiatx.com
Industry: Biotechnology Research
Employees: 29
Funding: 67.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

with Community Servings

About Delphia Therapeutics

Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.

Delphia Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 2; 50.0% coverage

Delphia Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Kevin Marks	Working to Transform Cancer Patient Care Through Activation Lethality @ Delphia Tx	Cambridge, Massachusetts, United States	Email Phone
Joseph Manna	Director, Dmpk	Bedford, Massachusetts, United States	Email
Brendan Veeneman	Director, Computational Biology at Delphia Therapeutics		View
Aimee Usera	SVP Head of Drug Discovery, Delphia Tx	Greater Boston, United States	Email Phone